Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIK cell immunotherapy + chemotherapy in squamous NSCLC
NCT01631357Phase 3Completed
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2014
- Primary completion
- Dec 2018
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 3 trial of unmodified CIK in squamous cell carcinoma of the lung (SCCL), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Dec 2014; status: completed.
02
Drugs
unmodified CIK
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT01631357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01631357.